Skip to content

Adial Pharmaceuticals, Inc.: 10-Q filed 2019-08-13

What Adial Pharmaceuticals, Inc. reported in its quarterly report filed 2019-08-13 (fiscal Q2 2019): 23 published measures, 68 facts as tagged in accession 0001213900-19-015413.

This filing

Form
10-Q (quarterly report)
Filed
2019-08-13
Fiscal period
fiscal Q2 2019
Accession
0001213900-19-015413 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Adial Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-06-3010,687,369USD
At 2018-12-314,699,285USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-06-3010,060,816USD
At 2019-03-3111,730,737USD
At 2018-12-314,441,311USD
At 2018-06-30-1,293,517USD
At 2018-03-31-1,307,342USD
At 2017-12-31-997,553USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-06-3010,254,023USD
At 2018-12-313,869,043USD
At 2018-06-30150,026USD
At 2017-12-3118,248USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-2,134,407USD91
2019-01-01 to 2019-06-30-4,817,058USD181
2018-04-01 to 2018-06-30-1,792,356USD91
2018-01-01 to 2018-06-30-2,171,306USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-01-01 to 2019-06-30-2,861,356USD181
2018-01-01 to 2018-06-30-403,222USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-01-01 to 2019-06-309,246,336USD181
2018-01-01 to 2018-06-30535,000USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-06-30-16,852,428USD
At 2018-12-31-12,035,370USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2019-01-01 to 2019-06-30748,464USD181
2018-01-01 to 2018-06-301,600,342USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-2,159,010USD91
2019-01-01 to 2019-06-30-4,408,276USD181
2018-04-01 to 2018-06-30-1,741,467USD91
2018-01-01 to 2018-06-30-2,080,980USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-06-3010,680,917USD
At 2018-12-314,692,550USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-06-30626,553USD
At 2018-12-31257,974USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2019-06-306,452USD
At 2018-12-316,735USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-04-01 to 2019-06-302,159,010USD91
2019-01-01 to 2019-06-304,408,276USD181
2018-04-01 to 2018-06-301,741,467USD91
2018-01-01 to 2018-06-302,080,980USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-04-01 to 2019-06-301,210,436USD91
2019-01-01 to 2019-06-301,897,350USD181
2018-04-01 to 2018-06-3076,895USD91
2018-01-01 to 2018-06-30132,403USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-06-3010,242,449shares
At 2018-12-316,862,499shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2019-06-3026,903,002USD
At 2018-12-3116,469,818USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2019-06-306,452USD
At 2018-12-316,735USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2019-06-30155,207USD
At 2018-12-31317,547USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-2,134,407USD91
2019-01-01 to 2019-06-30-4,817,058USD181
2018-04-01 to 2018-06-30-1,792,356USD91
2018-01-01 to 2018-06-30-2,171,306USD181

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-2,134,407USD91
2019-01-01 to 2019-03-31-2,682,651USD90
2018-04-01 to 2018-06-30-1,792,356USD91
2018-01-01 to 2018-03-31-378,950USD90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-04-01 to 2019-06-30948,574USD91
2019-01-01 to 2019-06-302,510,926USD181
2018-04-01 to 2018-06-301,664,572USD91
2018-01-01 to 2018-06-301,948,577USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2019-01-01 to 2019-06-30283USD181
2018-01-01 to 2018-06-30281USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2019-04-01 to 2019-06-3024,603USD91
2019-01-01 to 2019-06-30-408,782USD181
2018-04-01 to 2018-06-30-50,889USD91
2018-01-01 to 2018-06-30-90,326USD181

Inspect the source

Entity
Adial Pharmaceuticals, Inc. / CIK 0001513525
Captured
2026-09-20T09:13:16.139Z
SEC response SHA-256
a18f3033034427d32ef6db390e21f05d7acd23d932b720bc7458a3fbeee3e90d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001513525.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))